Chemours Co (CC) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Chemours Co (CC) stock forecast summary
Our AI ranks Chemours Co outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Chemours Co is a small-cap company with a market capitalization of $1.99B. It ranks number 5 by market capitalization among the 15 Chemicals & Allied Products issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for CC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CC included.
Follow CC freeCC price chart and AI forecast
How CC ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Chemours Co (CC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Chemicals & Allied Products peers listed below that report each metric.
Valuation & Market
| Metric | CC | Rank |
|---|---|---|
| Market Cap | $1.99B | 5/15 |
| Dividend Yield | 8.10% | 2/5 |
| EPS | $-1.84 | – |
| Revenue/Share | $38.52 | – |
| FCF/Share | $1.45 | – |
Profitability & Margins
| Metric | CC | Rank |
|---|---|---|
| ROA | -4.3% | 4/13 |
| Gross Margin | 15.3% | 11/14 |
| Net Margin | -5.3% | 4/13 |
| EBT Margin | -0.7% | 5/14 |
| Tax Rate | -682.0% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | CC | Rank |
|---|---|---|
| Current Ratio | 1.66x | 8/14 |
| Quick Ratio | 0.88x | 10/13 |
| Working Capital | $1.23B | 2/14 |
Cash Flow
| Metric | CC | Rank |
|---|---|---|
| Operating Cash Flow | $397M | 1/15 |
| Free Cash Flow | $218M | 1/9 |
| Capital Spending | -$179M | 8/9 |
| OCF Growth YoY | 53.9% | 1/8 |
| FCF/Sales | 3.8% | 4/9 |
| CapEx/Sales | 3.1% | 6/9 |
Operational Efficiency
| Metric | CC | Rank |
|---|---|---|
| Asset Turnover | 0.81x | 3/13 |
| Receivables Turnover | 7.5x | 3/10 |
| Inventory Turnover | 3.4x | 10/13 |
| Fixed Assets Turnover | 1.9x | 9/13 |
| Days Sales Outstanding | 49 days | 8/10 |
| Days Inventory | 108 days | 4/13 |
| Payables Period | 70 days | 4/10 |
| Cash Conversion Cycle | 87 days | 4/7 |
Income Statement
| Metric | CC | Rank |
|---|---|---|
| Total Revenue | $5.80B | 2/13 |
| Net Income | -$308M | 10/13 |
| R&D Expense | $106M | 3/10 |
| SG&A Expense | $855M | 1/13 |
| Cost of Goods Sold | $4.91B | 3/14 |
Dividend & Shareholder Information
| Metric | CC | Rank |
|---|---|---|
| Dividends Per Share | $1.07 | – |
| Shares Outstanding | 150M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3.09B | 43.3% of assets |
| Cash & Short-term Investments | $671M | 9.4% of assets |
| Accounts Receivable | $773M | 10.8% of assets |
| Inventory | $1.45B | 20.3% of assets |
| Total Liabilities | $7.20B | 100.7% of assets |
| Short-term Debt | $924M | 12.9% of assets |
CC quarterly financials and insider trading
Chemours Co (CC) industry peers
Companies classified under the same SEC industry code as Chemours Co (Chemicals & Allied Products): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CC Chemours Co | ▼ | $1.99B |
| BCPC Balchem Corp | ▼ | $5.41B |
| PRM Perimeter Solutions, Inc. | ▲ | $4.50B |
| NGVT Ingevity Corp | ▶ | $2.41B |
| IOSP Innospec Inc. | ▼ | $2.40B |
| OLN Olin Corp | ▶ | $1.69B |
| HUN Huntsman Corp | ▶ | $1.43B |
| ECVT Ecovyst Inc. | ▲ | $1.09B |
| FMC Fmc Corp | ▶ | $1.04B |
| SLI Standard Lithium Ltd. | ▼ | $343M |
| ADUR Aduro Clean Technologies Inc. | ▶ | $307M |
| ACNT Ascent Industries Co. | ▲ | $122M |
| LQMT Liquidmetal Technologies Inc | ▼ | $83M |
| BLGO Biolargo, Inc. | ▲ | $26M |
| GURE Gulf Resources, Inc. | ▶ | $5M |
| CITR Citrotech Inc. | ▶ | N/A |
| LOOP Loop Industries, Inc. | ▶ | N/A |
Where CC sits on the market map
Chemours Co (CC) stock news
Loading...
Chemours Co (CC) stock forecast FAQ
What is the Chemours Co (CC) stock forecast?
Our AI ranks Chemours Co outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Chemours Co stock predictions?
A per-ticker accuracy statistic for CC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Chemours Co forecasts updated?
Chemours Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Chemours Co's industry peers?
17 issuers in our coverage, CC included, share the SEC industry code Chemicals & Allied Products. The largest are: Balchem Corp (BCPC), Perimeter Solutions, Inc. (PRM), Ingevity Corp (NGVT), Innospec Inc. (IOSP), Olin Corp (OLN), Huntsman Corp (HUN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.